Sarepta Therapeutics, Inc. 8-K

What Happened
Sarepta Therapeutics (SRPT) announced on January 12, 2026 that it issued a press release disclosing business updates and preliminary financial information for the year and fiscal quarter ended December 31, 2025. The press release was furnished with the company’s Form 8‑K in connection with the 44th Annual J.P. Morgan Healthcare Conference. The Form 8‑K was signed by CEO Douglas S. Ingram.

Key Details

• Press release dated January 12, 2026 furnished as Exhibit 99.1 to the Form 8‑K.
• Disclosure covers preliminary financial information "as of and for the year and fiscal quarter ended December 31, 2025."
• Announcement was made in connection with the 44th Annual J.P. Morgan Healthcare Conference.
• Form 8‑K was executed by CEO Douglas S. Ingram on January 12, 2026.

Why It Matters
This filing gives investors an early, company‑issued update on Sarepta’s recent earnings and financial condition (preliminary results for Q4/FY 2025). Such updates can influence expectations for revenue and quarterly results ahead of formal, audited filings and broader investor disclosures. Retail investors should read the attached press release (Exhibit 99.1) for the specific preliminary figures and watch for subsequent official filings for full, audited financials.